What is the 13F Pro Quality Score for AKBA?

13F Pro ranks Akebia Therapeutics, Inc. (AKBA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AKBA's current score at https://13fpro.ai/research/AKBA (free sign-up required for the full ranking).

Which hedge funds own the most AKBA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AKBA include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AKBA as soon as new 13F filings post.

Where does 13F Pro source AKBA data?

All Akebia Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Akebia Therapeutics, Inc. files with the SEC under CIK 1517022. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AKBA in?

Akebia Therapeutics, Inc. (AKBA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AKBA research updated on 13F Pro?

AKBA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Akebia Therapeutics, Inc.(AKBA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1517022 AKBA stock profile & AI dashboard →

13F Pro Quality Score

46.4/100

Rank #1,653 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

77.3/100

Profitability

51.4/100

Balance Sheet

33.6/100

Earnings Quality

30.0/100

Free Cash Flow

55.3/100

Institutional Flow

11.9/100

Revenue Scale

25.9/100

Dilution Risk

26.6/100

AKBA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Akebia Therapeutics, Inc. (AKBA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AKBA at 46.4/100 on a 32-signal composite quality model, placing it at rank #1,653 of 2,879 stocks — the bottom half of the AI-ranked universe. AKBA scores in the top quartile across revenue growth (77.3). Areas of concern include institutional flow (11.9) and revenue scale (25.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Akebia Therapeutics, Inc. reports quarterly revenue of $53.5M, net income of $-9.1M, free cash flow of $-21.3M. Top institutional holders of AKBA by reported 13-F value include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. AKBA trades on the Nasdaq exchange and files with the SEC under CIK 1517022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKBA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akebia Therapeutics, Inc. directly from SEC EDGAR. Akebia Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 11 and 50 since 2021, currently 46.4 — an improving long-term trajectory across 54 quarterly and live scoring snapshots.

✦

Fun facts about Akebia Therapeutics, Inc.

Quirks, history, and lore behind AKBA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the tens of millions of dollars — the profile of a company still fighting to prove its lead drug can carry the whole business.
3
The History
Founded in the 2000s, it spent years developing therapies targeting chronic kidney disease, a condition affecting hundreds of millions of people worldwide.
4
The Secret
Its core science centers on the HIF pathway — hypoxia-inducible factor — a molecular switch the body uses to respond to low oxygen levels, which also governs red blood cell production.
5
The Lore
Its lead drug, a HIF prolyl hydroxylase inhibitor, went head-to-head with dialysis-era anemia treatments in a notably rocky regulatory journey with the FDA — a saga that tested investors' patience for years.
6
The Giveaway
The company's name is a mashup of two Greek roots meaning 'no' and 'life' — fitting for a firm obsessed with what happens when kidneys fail and blood stops carrying enough oxygen.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$53.5M

Net Income

Q1 2026

$-9.1M

Free Cash Flow

Q1 2026

$-21.3M

ROIC

Q1 2026

-6.2%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-17.7% YoY

$160.2MFY 2024

FY21 $213.6MFY22 $292.5MFY23 $194.6MFY24 $160.2M

Net Income

-33.7% YoY

$-69.4MFY 2024

FY21 $-282.8MFY22 $-94.2MFY23 $-51.9MFY24 $-69.4M

Operating Income

-9.1% YoY

$-50.5MFY 2024

FY21 $-265.3MFY22 $-80.8MFY23 $-46.3MFY24 $-50.5M

EPS (Diluted)

-17.9% YoY

$-0.33FY 2024

FY21 $-1.70FY22 $-0.52FY23 $-0.28FY24 $-0.33

Total Assets

-8.7% YoY

$220.7MFY 2024

FY21 $525.5MFY22 $356.1MFY23 $241.7MFY24 $220.7M

Total Debt

-25.9% YoY

$38.7MFY 2024

FY21 $195.1MFY22 $98.1MFY23 $52.2MFY24 $38.7M

Op. Cash Flow

-73.9% YoY

$-40.7MFY 2024

FY21 $-253.0MFY22 $-73.2MFY23 $-23.4MFY24 $-40.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$160.2M -17.7%	$194.6M -33.5%	$292.5M +36.9%	$213.6M -36.2%	$335.0M +61.3%	$207.7M
Net Income	$-69.4M -33.7%	$-51.9M +44.9%	$-94.2M +66.7%	$-282.8M -1.1%	$-279.7M -94.8%	$-143.6M
Operating Income	$-50.5M -9.1%	$-46.3M +42.7%	$-80.8M +69.6%	$-265.3M +7.3%	$-286.3M -60.7%	$-178.2M
EPS (Diluted)	$-0.33 -17.9%	$-0.28 +46.2%	$-0.52 +69.4%	$-1.70 +28.0%	$-2.36	—
Total Assets	$220.7M -8.7%	$241.7M -32.1%	$356.1M -32.3%	$525.5M -31.9%	$771.2M -22.6%	$996.5M
Total Debt	$38.7M -25.9%	$52.2M -46.8%	$98.1M -49.7%	$195.1M +157.4%	$75.8M +405.4%	$15.0M
Operating Cash Flow	$-40.7M -73.9%	$-23.4M +68.0%	$-73.2M +71.1%	$-253.0M +1.7%	$-257.4M -164.1%	$-97.5M

Get alerted when AKBA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Akebia Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AKBA

BlackRock, Inc.
$26.0M18,693,296 sh
STATE STREET CORP
$16.1M11,614,006 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.5M11,166,710 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.0M6,452,252 sh
GOLDMAN SACHS GROUP INC
$5.0M3,602,827 sh
CITIGROUP INC
$4.0M2,854,586 sh
BANK OF AMERICA CORP /DE/
$3.8M2,763,362 sh
Qube Research & Technologies Ltd
$3.3M2,395,215 sh
MILLENNIUM MANAGEMENT LLC
$3.3M2,384,713 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$3.1M2,215,441 sh

Fund	Value	Shares
BlackRock, Inc.	$26.0M	18,693,296
STATE STREET CORP	$16.1M	11,614,006
VANGUARD CAPITAL MANAGEMENT LLC	$15.5M	11,166,710
GEODE CAPITAL MANAGEMENT, LLC	$9.0M	6,452,252
GOLDMAN SACHS GROUP INC	$5.0M	3,602,827
CITIGROUP INC	$4.0M	2,854,586
BANK OF AMERICA CORP /DE/	$3.8M	2,763,362
Qube Research & Technologies Ltd	$3.3M	2,395,215
MILLENNIUM MANAGEMENT LLC	$3.3M	2,384,713
VANGUARD PORTFOLIO MANAGEMENT LLC	$3.1M	2,215,441

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AKBA on your watchlist

Track score changes the day Akebia Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AKBA a good stock to buy?

13F Pro's AI-powered analysis of Akebia Therapeutics, Inc. (AKBA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AKBA are available on the AKBA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AKBA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AKBA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Akebia Therapeutics, Inc.'s investment landscape.